Abstract:Asthma, a disease intricately linked to immune inflammation, is significantly influenced by the immune regulatory effect of bone mesenchymal stem cells (BMSCs). This study aims to investigate changes in the homing of BMSCs in bronchial asthma, focusing on the Notch homolog (Notch)1/Jagged1 signaling pathway's role in regulating T helper 1(Th1)/T helper 2(Th2) drift. Additionally, we further explore the effects and mechanisms of homologous BMSCs implantation in asthma-related immune inflammation. Following intervention with BMSCs, a significant improvement in the pathology of rats with asthma was observed. Simultaneously, a reduction in the expression of inflammatory cells and inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin(IL)-4, and IL-13 was observed in bronchoalveolar lavage fluid (BALF). Furthermore, there was an increase in the expression of Th1 cytokine Interferon-γ(IFN-γ)and the transcription factor T-box expressed in T cell (T-bet), while the expression of Th2 cytokine IL-13 and transcription factor GATA binding protein (GATA)-3 decreased in lung tissue. This indicates that the Th1/Th2 drift leans towards Th1, which a crucial in ameliorating asthma inflammation. Importantly, inhibition of the Notch1 signaling pathway led to an increased expression of the Stromal cell-derived factor-1(SDF-1)/C-X-C motif chemokine receptor (CXCR)4 chemokine axis. Consequently, the homing ability of bone marrow mesenchymal stem cells to asthma-affected lung tissue was significantly enhanced. BMSCs demonstrated heightened efficacy in regulating the cytokine/chemokine network and Th1/Th2 balance, thereby restoring a stable state during the immune response process in asthma. In conclusion, inhibiting the Notch signaling pathway enhances the expression of the SDF-1 and CXCR4 chemokine axis, facilitating the migration of allogeneic BMSCs to injured lung tissues. This, in turn, promotes immune regulation and improves the Th1/Th2 imbalance, thereby enhancing the therapeutic effect on asthmatic airway inflammation.

Cellular precision modulation of JAK1: tailoring therapies for allergic lung inflammation

New Therapeutics for Allergic Airway Diseases

Targeting cell signaling in allergic asthma

Inhibition of P21-Activated Kinase 1 Attenuates the Cardinal Features of Asthma Through Suppressing the Lymph Node Homing of Dendritic Cells.

Tailoring lipid nanoparticles for T-cell targeting in allergic Asthma: Insights into efficacy and specificity

Regulatory T Cells, a Viable Target Against Airway Allergic Inflammatory Responses in Asthma

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Site-specific inhibition of neutrophilic inflammation by low-dose nanotherapy for immunoregulatory treatment of asthma

Targeted siRNA delivery to lung epithelia reduces airway inflammation in a mouse model of allergic asthma

Modulating ILC2 function for treatment of type 2 airway diseases

Allosteric inhibition of CXCR1 and CXCR2 abrogates Th2/Th17-associated Allergic Lung Inflammation in Mice

Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells

Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond

JAK1 hits a nerve

Current research into A20 mediation of allergic respiratory diseases and its potential usefulness as a therapeutic target

Exploring the therapeutic potential of monoclonal antibodies targeting TSLP and IgE in asthma management

Modulating Th1/Th2 drift in asthma-related immune inflammation by enhancing bone mesenchymal stem cell homing through targeted inhibition of the Notch1/Jagged1 signaling pathway

T-helper cells and their cytokines in pathogenesis and treatment of asthma

Biologics in Asthma: A Molecular Perspective to Precision Medicine

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer